We’re excited to be joining the World Vaccine Congress Europe 2026!
INFECTA is an impact-driven clinical research organization focused on accelerating the development of infectious disease products through early-phase clinical testing and controlled human infection models.
We provide services for the development of vaccines, therapeutics, antivirals and biologics, combining early-phase clinical research with scientific expertise, regulatory knowledge and a broad academic network.
The INFECTA Team is ready to meet the vaccine community in Amsterdam!
Meet Meta Roestenberg, Ingrid de Visser-Kamerling, Aneta Karczmarek, Mo Weijtens en Wilfried Bakker at booth 414 to exchange ideas, explore new collaborations and discuss your development program.
booth
414
INFECTA CEO Prof. Dr. Meta Roestenberg will present:
“Controlled Human Infection Models for RSV and Clostridioides difficile: Interim Results from Inno4Vac”
21 October | 14:15 | Track 3
Meta brings extensive experience as an infectious disease physician and professor specialized in Controlled Human Infection Models for vaccine development.
Join her session to hear more about the interim results of the Controlled Human Infection Models for RSV and Clostridioides difficile developed within the Inno4Vac consortium.
Our COO Dr. Ingrid de Visser-Kamerling is participating in a panel to join the discussion on CHIMs, which will be moderated by Bassam Hallis from UKHSA. Ingrid has extensive expertise in early phase clinical research for infectious diseases products and actively contributes to international consortia including Inno4Vac, Fluniversal, and MUSSIC.
21th October | 13.30 | Track 3
Would you like to continue the conversation afterwards? Meet the INFECTA team at booth 414!
Meta Roestenberg
Ingrid de Visser-Kamerling
Missed Meta Roestenberg’s presentation at the World Vaccine Congress Europe, or want to revisit her key insights?
Download a summary from her presentation Controlled Human Infection Models for RSV and Clostridioides difficile: Interim Results from Inno4Vac after the WVC.
If you want to learn more or discuss Control Human Infection Models with our team? Contact us!
INFECTA is a full-service early-phase CRO building on almost forty years of experience in healthy-volunteer studies.
We design your trial, draft the protocol and submission package, and guide it through the regulatory process according to the agreed timelines and standards. Trials are conducted by our own team under the latest ICH-GCP guidance, with transparent updates at every step.
INFECTA has extensive experience performing CHIM studies and holds a broad portfolio of Controlled Human Infection Models. CHIMs can be used to study host-pathogen interactions and test the efficacy of novel therapeutics and vaccines. When appropriate and ethically approved, they can enable early, decision-quality read-outs in infectious-disease product development.
Building on decades of experience in early-phase development, INFECTA supports the development path from candidate to first-in-human and beyond.
Professor Dr. Meta Roestenberg
CEO
Dr. Ingrid de Visser-Kamerling
COO
Dr. Mo Weijtens
Sr. Program Manager
Dr. Aneta Karczmarek
Director of Business Development
Dr. Ir. Wilfried Bakker
Director Infectory
